Alkem Laboratories Ltd. (IN:ALKEM)
:ALKEM
Want to see IN:ALKEM full AI Analyst Report?
ALKEM Stock Chart & Stats
₹5558.15
-₹65.00(-1.17%)
At close: 4:00 PM EST
₹5558.15
-₹65.00(-1.17%)
Day’s Range― - ―
52-Week Range₹4,716.75 - ₹5,933.00
Previous CloseN/A
Volume39.00K
Average Volume (3M)9.84K
Market Cap
₹633.88B
Enterprise Value₹675.36B
Total Cash (Recent Filing)₹51.52B
Total Debt (Recent Filing)₹23.56B
Price to Earnings (P/E)27.5
Beta0.55
Next Earnings
Aug 07, 2026EPS Estimate
49.1Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)197.47
Shares Outstanding119,565,000
10 Day Avg. Volume12,022
30 Day Avg. Volume9,843
Financial Highlights & Ratios
PEG Ratio4.33
Price to Book (P/B)4.54
Price to Sales (P/S)4.26
P/FCF Ratio46.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹6,416.67Price Target Upside15.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)197.97
Revenue Forecast (FY)₹165.28B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~13.5% revenue growth rate reflects steady top-line expansion and a recent pickup, indicating durable demand for products. Sustained revenue momentum supports reinvestment in sales, manufacturing scale and new market launches over the next several months.
Conservative Balance SheetLow leverage and a conservatively positioned balance sheet preserve financial flexibility. This reduces refinancing and interest risk, enabling the company to fund capex, acquisition opportunities or absorb shocks without compromising long-term operations or R&D investments.
Solid Profitability And ReturnsConsistently healthy margins and robust ROE indicate efficient operations and pricing power in core therapies. Strong profitability supports internal cash for growth initiatives, sustained commercial investments and the capacity to maintain competitive positioning across markets.
Bears Say
Weak Cash ConversionFree cash flow lagging reported earnings signals working-capital intensity or reinvestment needs that reduce cash available for discretionary uses. Over months this can constrain dividends, share buybacks or incremental M&A, and raises sensitivity to cyclical pressures.
Margin VolatilityYear-to-year margin swings imply exposure to pricing, input-cost or mix shifts that can erode predictability. For a pharmaceutical company, this amplifies forecasting risk for earnings and cash flow, complicating long-term planning and capital allocation decisions.
Concentration In Branded Generics And Regulated MarketsHeavy reliance on branded generics and U.S. product approvals creates structural execution risk: delayed approvals, regulatory changes or intense generic competition can materially affect revenue trajectories and timing of international growth over the medium term.
Alkem Laboratories Ltd. News
ALKEM FAQ
What was Alkem Laboratories Ltd.’s price range in the past 12 months?
Alkem Laboratories Ltd. lowest stock price was ₹4716.75 and its highest was ₹5933.00 in the past 12 months.
What is Alkem Laboratories Ltd.’s market cap?
Alkem Laboratories Ltd.’s market cap is ₹633.88B.
When is Alkem Laboratories Ltd.’s upcoming earnings report date?
Alkem Laboratories Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.
How were Alkem Laboratories Ltd.’s earnings last quarter?
Alkem Laboratories Ltd. released its earnings results on May 28, 2026. The company reported ₹19.8 earnings per share for the quarter, missing the consensus estimate of ₹35.461 by -₹15.661.
Is Alkem Laboratories Ltd. overvalued?
According to Wall Street analysts Alkem Laboratories Ltd.’s price is currently Undervalued.
Does Alkem Laboratories Ltd. pay dividends?
Alkem Laboratories Ltd. pays a Semiannually dividend of ₹43 which represents an annual dividend yield of 0.8%. See more information on Alkem Laboratories Ltd. dividends here
What is Alkem Laboratories Ltd.’s EPS estimate?
Alkem Laboratories Ltd.’s EPS estimate is 49.1.
How many shares outstanding does Alkem Laboratories Ltd. have?
Alkem Laboratories Ltd. has 119,565,000 shares outstanding.
What happened to Alkem Laboratories Ltd.’s price movement after its last earnings report?
Alkem Laboratories Ltd. reported an EPS of ₹19.8 in its last earnings report, missing expectations of ₹35.461. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alkem Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:ALKEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alkem Laboratories Ltd.
Alkem Laboratories Ltd. functions as a pharmaceutical enterprise, engaged in the research, manufacturing, and worldwide distribution of both medicinal and nutritional products. Its comprehensive offerings encompass a variety of branded and generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and nutraceuticals. These products target both immediate and chronic health issues across numerous therapeutic areas, including anti-infectives, skin conditions, cardiovascular health, respiratory ailments, digestive problems, central nervous system disorders, cancer, urology, and women's health. The company also provides essential vitamins, minerals, and nutritional supplements, in addition to pain relief medications, anti-diabetic treatments, and neurological remedies. Complementing its core pharmaceutical lines, Alkem offers consumer health items such as pregnancy detection kits and condoms. Founded in 1973, the company's headquarters are located in Mumbai, India.
ALKEM Stock 12 Month Forecast
Average Price Target
₹6,416.67
▲(15.45% Upside)
Technical Analysis
Abbott India Limited
―
Aurobindo Pharma Ltd
―
Caplin Point Laboratories Limited
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―